Cempra
Manufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6340 Quadrangle Dr Ste 100, Chapel Hill,...Phone Number
(312) 767-0291Website
www.cempra.comRevenue
$17.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Cempra
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases in North America. Its lead product candidate is solithromycin, which is in Phase III clinical trials developed in oral capsules, intravenous, and suspension formulations for the treatment of community-acquired bacterial pneumonia in adults and children, as well as for ophthalmic infections and other indications. The company is also developing fusidic acid, an antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. In addition, it is developing other uses for solithromycin and fusidic acid, as well as analogs from its macrolide platform for non-infectious disease programs; and macrolides for treating diabetic gastroparesis and gastroesophageal reflux disease. It has a collaborative research and development and licenseRead more
Cempra Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cempra your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Cempra has new funding data
Congratulate Masked Content for being promoted to Masked Content at Cempra
Product Launch: Get notified when Cempra launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Cempra is spiking on competitors!
Check if Cempra has recently received funding, and reach out quickly before it becomes old news!
Cempra, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Cempra recently announced quarterly report
Click to see if Cempra had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Cempra
Find more new buyers
Compare Similar Companies to Cempra
Compare insights from companies similar to Cempra, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cempra is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cempra is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cempra.
Cempra financials insights
Gather financial insights about Cempra, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series B
$10M
2009
Private Equity
$25.5M
Series C
$46M
2011
Debt
$5M
2012
Stock Offering
$50.4M
Private Equity
$25.1M
2016
Private Equity
$10M
2020
Series A
$22M
Cempra Tech Stack
A closer look at the technologies used by Cempra
See more technologies
Cempra News & Media
Hercules Capital Achieves More Than $880 Million in New Commitments in 2017(1)
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty finance company to innovative venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, today announced its portfolio update for the fourth quarter and full-year 2017. “We witnessed unprecedented activity in both new commitments and early pay-offs during the fourth quarter and full year 2017,” stated Manuel A. Henriquez, founder, chairmaCempra Announces Preliminary Results of 2017 Stockholder Vote
CHAPEL HILL, N.C., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment of infectious diseases, today announced the preliminary results of its stockholder vote at the company’s 2017 annual meeting of stockholders held today. Among other proposals, Cempra stockholders approved the issuance of Cempra common stockHercules Announces Third Quarter 2017 Financial Results and Declares a $0.31 per Share Quarterly Distribution
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the third quarter ended September 30, 2017. The Company also announced that its Board of Directors has declared a third quarter cash distribution of $0.31 per share, that will be payable on November 20, 2017, to shareholders ofMelinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization
NEW HAVEN, Conn. and CHAPEL HILL, N.C., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, and Cempra, Inc. (Nasdaq:CEMP) today announced the executive leadership team for the combined Melinta and Cempra business, which will keep the name Melinta Therapeutics upon the closing of the merger.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cempra
Sign Up For FreeTo access detailed company insights
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases in North America. Its lead product candidate is solithromycin, which is in Phase III clinical trials developed in oral capsules, intravenous, an... Read More
